Product Description
Methoxamine is a pharmaceutical drug developed for the treatment of hypotension, or low blood pressure. It increases systolic and diastolic blood pressure in patients who experience low blood pressure due to spinal anesthesia, hemorrhage, reaction to medicine, complications from surgery, or physical trauma or tumors. (Sourced from: https://americanaddictioncenters.org/synthetic-drugs/methoxamine)
Mechanisms of Action: ADRA1A Agonist,ADRA1B Agonist,ADRA1D Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intramuscular,Intravenous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Canada | China | Ireland | Italy | New Zealand | Pakistan | United Kingdom
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|